Core Diagnostics offers over 1,300 high-end tests, with a primary focus on cancer, serving more than 6,000 speciality prescribers, including 1,600+ top cancer specialists. Shares of Metropolis Healthcare Ltd ended at ₹2,187, up by ₹51.15, or 2.39%, on the BSE.
